UCORIS is a phase 2, open-label, two-center, prospective, single arm, investigator-initiated proof of concept study of orismilast in adult patients with moderate to severe UC

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

21 Feb 2025 According to an UNION therapeutics media release, company announced a poster presentation on new clinical data of oral orismilast in patients with UC at the 20th European Crohns and Colitis Organisation (ECCO) congress on February 19-22, 2025, in Berlin, Germany.
12 Feb 2024 New trial record
04 Jan 2024 According to an UNION therapeutics media release, The FDA has cleared UNIONs Investigational New Drug (IND) application for oral orismilast.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com